Comparison of protein kinase C activity and isoform expression in cisplatin‐sensitive and ‐resistant ovarian carcinoma cells

Alakananda Basu, Kelly M. Weixel

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Cellular sensitivity to cis‐diamminedichloroplatinum(II) (cDDP) can be regulated by protein kinase C (PKC) signal transduction pathway. Activators of PKC were shown to en‐ hance the sensitivity of human ovarian carcinoma 2008 cells to cDDP. We have examined whether or not the PKC signal transduction pathway is affected during‐development of resistance by tumor cells to cDDP. A 2‐fold decrease in PKC activity was observed in cDDP‐resistant ovarian carcinoma 2008 J. C13*5.25 cells compared with the drug‐sensitive 2008 cells. Subceflular distribution studies revealed a reduction in both cytosolic and paniculate PKC activities in 2008/C13*5.25 cells. The pattern of PKC isoform expression was compared in cDDP‐sensitive and ‐resistant cell lines by Western blot analysis with isoform‐specific antibodies to PKC. The parental cells expressed PKCα, ‐ε, and ‐ζ isoforms. The abundance of PKCα decreased significantly in 2008/C 13*5.25 cells, whereas the amount of PKCe increased moderately in the resistant variant, with no alteration in PKCε content. Therefore, a reduction in PKCa and/or an increase in PKCε expression may be associated with the drug‐resistant phenotype. © 1995 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)457-460
Number of pages4
JournalInternational Journal of Cancer
Volume62
Issue number4
DOIs
StatePublished - 1 Jan 1995

Fingerprint

Protein Kinase C
Protein Isoforms
Carcinoma
Signal Transduction
Western Blotting
Phenotype
Cell Line
Antibodies

Cite this

@article{b7fe3c7f8d184fb0bdf755679d0a79c3,
title = "Comparison of protein kinase C activity and isoform expression in cisplatin‐sensitive and ‐resistant ovarian carcinoma cells",
abstract = "Cellular sensitivity to cis‐diamminedichloroplatinum(II) (cDDP) can be regulated by protein kinase C (PKC) signal transduction pathway. Activators of PKC were shown to en‐ hance the sensitivity of human ovarian carcinoma 2008 cells to cDDP. We have examined whether or not the PKC signal transduction pathway is affected during‐development of resistance by tumor cells to cDDP. A 2‐fold decrease in PKC activity was observed in cDDP‐resistant ovarian carcinoma 2008 J. C13*5.25 cells compared with the drug‐sensitive 2008 cells. Subceflular distribution studies revealed a reduction in both cytosolic and paniculate PKC activities in 2008/C13*5.25 cells. The pattern of PKC isoform expression was compared in cDDP‐sensitive and ‐resistant cell lines by Western blot analysis with isoform‐specific antibodies to PKC. The parental cells expressed PKCα, ‐ε, and ‐ζ isoforms. The abundance of PKCα decreased significantly in 2008/C 13*5.25 cells, whereas the amount of PKCe increased moderately in the resistant variant, with no alteration in PKCε content. Therefore, a reduction in PKCa and/or an increase in PKCε expression may be associated with the drug‐resistant phenotype. {\circledC} 1995 Wiley‐Liss, Inc.",
author = "Alakananda Basu and Weixel, {Kelly M.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/ijc.2910620416",
language = "English",
volume = "62",
pages = "457--460",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Comparison of protein kinase C activity and isoform expression in cisplatin‐sensitive and ‐resistant ovarian carcinoma cells. / Basu, Alakananda; Weixel, Kelly M.

In: International Journal of Cancer, Vol. 62, No. 4, 01.01.1995, p. 457-460.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of protein kinase C activity and isoform expression in cisplatin‐sensitive and ‐resistant ovarian carcinoma cells

AU - Basu, Alakananda

AU - Weixel, Kelly M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Cellular sensitivity to cis‐diamminedichloroplatinum(II) (cDDP) can be regulated by protein kinase C (PKC) signal transduction pathway. Activators of PKC were shown to en‐ hance the sensitivity of human ovarian carcinoma 2008 cells to cDDP. We have examined whether or not the PKC signal transduction pathway is affected during‐development of resistance by tumor cells to cDDP. A 2‐fold decrease in PKC activity was observed in cDDP‐resistant ovarian carcinoma 2008 J. C13*5.25 cells compared with the drug‐sensitive 2008 cells. Subceflular distribution studies revealed a reduction in both cytosolic and paniculate PKC activities in 2008/C13*5.25 cells. The pattern of PKC isoform expression was compared in cDDP‐sensitive and ‐resistant cell lines by Western blot analysis with isoform‐specific antibodies to PKC. The parental cells expressed PKCα, ‐ε, and ‐ζ isoforms. The abundance of PKCα decreased significantly in 2008/C 13*5.25 cells, whereas the amount of PKCe increased moderately in the resistant variant, with no alteration in PKCε content. Therefore, a reduction in PKCa and/or an increase in PKCε expression may be associated with the drug‐resistant phenotype. © 1995 Wiley‐Liss, Inc.

AB - Cellular sensitivity to cis‐diamminedichloroplatinum(II) (cDDP) can be regulated by protein kinase C (PKC) signal transduction pathway. Activators of PKC were shown to en‐ hance the sensitivity of human ovarian carcinoma 2008 cells to cDDP. We have examined whether or not the PKC signal transduction pathway is affected during‐development of resistance by tumor cells to cDDP. A 2‐fold decrease in PKC activity was observed in cDDP‐resistant ovarian carcinoma 2008 J. C13*5.25 cells compared with the drug‐sensitive 2008 cells. Subceflular distribution studies revealed a reduction in both cytosolic and paniculate PKC activities in 2008/C13*5.25 cells. The pattern of PKC isoform expression was compared in cDDP‐sensitive and ‐resistant cell lines by Western blot analysis with isoform‐specific antibodies to PKC. The parental cells expressed PKCα, ‐ε, and ‐ζ isoforms. The abundance of PKCα decreased significantly in 2008/C 13*5.25 cells, whereas the amount of PKCe increased moderately in the resistant variant, with no alteration in PKCε content. Therefore, a reduction in PKCa and/or an increase in PKCε expression may be associated with the drug‐resistant phenotype. © 1995 Wiley‐Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0029086492&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910620416

DO - 10.1002/ijc.2910620416

M3 - Article

C2 - 7635571

AN - SCOPUS:0029086492

VL - 62

SP - 457

EP - 460

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -